A Long-term Efficacy Assessment Following Initial Scar Revision Surgery And Phase 2 Open-label Study To Evaluate Safety Of Re-treatment With Pf-06473871
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2016
Price : $35 *
At a glance
- Drugs PF 6473871 (Primary)
- Indications Hypertrophic scars
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 26 Jan 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 17 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
- 24 Nov 2014 Planned End Date changed from 1 Nov 2015 to 1 Oct 2015 according to ClinicalTrials.gov record.